Neurodegenerative Diseases



dynaCERT Inc.
Latest Comments
image_pdfimage_print

Steve Saviuk of Valeo Pharma on record 2021 revenues, achieving breakeven in 2022, and uplisting on the TSX

In a recent InvestorIntel interview, Tracy Weslosky spoke with Steve Saviuk, CEO of Valeo Pharma Inc. (CSE: VPH | OTCQB: VPHIF) about […]


Valeo Pharma is cashed up and ready to expand as COVID restrictions end

Are we starting to see the beginning of the end of COVID’s reign of terror over humanity? I certainly hope […]


XPhyto Therapeutics is looking to hit a home run with their innovative medical products and therapies

New therapies and diagnostics in the pharmaceutical and medical industries can be a very lucrative area. To be successful a […]


Revenue is forecast to triple, Valeo Pharma has 10 products in their portfolio

COVID-19 continues to be a huge global problem with global cases now over 112 million. Vaccines are a source of […]


Valeo Pharma on a significant upswing with recent Health Canada approvals

In a new InvestorIntel interview Peter Clausi speaks with Steve Saviuk, CEO of Valeo Pharma Inc. (CSE: VPH | OTCQB: […]